EU-FUNDED PROJECT | IN2SIGHT

IN2SIGHT is a project that fosters an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.

IN2SIGHT is a project that fosters an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.
September 23, 2021

IN2SIGHT is a project that fosters an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.

The project will allow unique quantification of the immune reaction to biomaterials at the cellular level (scientific impact), largely reducing the ethical burden of the research and the costs of biomaterial discovery (economical impact), and will Refine and Reduce protocols for biocompatibility on a single revolutionary device (regulatory impact).

Yesterday, Marta Rayo Lunar and Luis Borges Rocha represented Asphalion at the 6-month consortium meeting of IN2SIGHT, an H2020 funded project, which took place online.

In the meeting, they had the opportunity to share Asphalion´s first deliverable with the other project partners.

For more information about the IN2SIGHT the project, including a short presentation video, we invite you to visit the project website: https://www.in2sight.eu/.

For any further information, you can contact us at: horizon@asphalion.com

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON | siNPAIN meeting in Reykjavík

The objective of this project is to create a siRNA-combined advanced therapy, which will allow a more personalised treatment for different stages of osteoarthritis.  All siNPAIN partners are working hard to develop efficient therapy to improve the quality of life of those affected by osteoarthritis, a chronic joint condition that affects more and more people every year.

EVENT | Symposium AEFI 2024

¡Mañana arranca el 42º Symposium de AEFI! No olvidéis visitarnos en la mesa 6 para conocer de todos los servicios que ofrecemos. Os recordamos los

PRAGMATIL | First annual progress meeting

The partners of the PragmaTIL consortium have gathered in Barcelona to hold its first annual meeting. Asphalion’s experts Montse Domingo and Nuria García Pazos attended

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting